Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI

• Status: Unknown status
• Trial end date: 2019-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomized, controlled trial compares the anti-thrombotic effect of cangrelor and ticagrelor on platelet activity in patients with acute ST-elevation myocardial infarction.

Patients will receive either prehospital ticagrelor (180 mg - crushed) or in-hospital cangrelor (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) followed by 180 mg ticagrelor.

The primary study end-point is platelet reactivity at sheath insertion, at the end of the PCI procedure (before sheath removal) and two hours after PCI is initiated. The secondary end-point is the proportion of patients with inappropriate or harmful P2Y12 administration.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Treatments: Cangrelor; Ticagrelor

Criteria

Inclusion Criteria:

1. Patients triaged for PPCI due to suspicion of STEMI.

2. Symptom duration < 12 hours

Exclusion Criteria:

1. Previous inclusion in the study

2. Already in treatment with ticagrelor, prasugrel or clopidogrel

3. Treatment with oral anticoagulants (warfarin, coumarins, rivaroxaban, apixaban, dabigatran)

4. Adjunctive use of glycoprotein IIb/IIIa inhibitor during PCI

5. Active bleeding

6. Known, severe kidney failure (GFR < 30 ml/min) and/or liver disease

7. Women of child bearing ability who are not using contraceptive medication

8. Severe mental or psychiatric disease, altered mental state (including unconsciousness) making it impossible to achieve informed consent